Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael L Cheng

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Cancer Immunology Research|January 26, 2024
Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with CancerHewitt Chang, Jaqueline Marquez, Brandon K Chen, et al.
Cancers|September 9, 2022
BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a TrialJohn Hilton, Mihaela Cristea, Sophie Postel-Vinay, et al.
Blood|October 27, 2025
Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AMLBogdan Popescu, Matthew F Jones, Madison Piao, et al.
Cellular and Molecular Gastroenterology and Hepatology|September 4, 2025
IL-4-mediated Pro-Regenerative Cellular Reprogramming in 3D Liver CultureDamra Camat, Diana Nakib, Sai W Chung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2025
The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 TrialAlison M Schram, Abdul Rafeh Naqash, Eric B Haura, et al.
NPJ Precision Oncology|February 14, 2024
Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapyCharlotte S Walmsley, Philip Jonsson, Michael L Cheng, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 28, 2023
Initial Chemotherapy for Locally Advanced and Metastatic NUT CarcinomaJia Luo, Michelle Sanchez, Elinton Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2022
Report of the First International Symposium on NUT CarcinomaChristopher A French, Michael L Cheng, Glenn J Hanna, et al.
The Oncologist|December 10, 2024
Associations of frailty with survival, hospitalization, functional decline, and toxicity among older adults with advanced non-small cell lung cancerHoward J Lee, John Boscardin, Louise C Walter, et al.
The New England Journal of Medicine|August 23, 2023
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a <i>KRAS</i> G12C MutationAdrian Sacher, Patricia LoRusso, Manish R Patel, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Cancer Immunology Research|January 26, 2024
Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with CancerHewitt Chang, Jaqueline Marquez, Brandon K Chen, et al.
Cancers|September 9, 2022
BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a TrialJohn Hilton, Mihaela Cristea, Sophie Postel-Vinay, et al.
Blood|October 27, 2025
Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AMLBogdan Popescu, Matthew F Jones, Madison Piao, et al.
Cellular and Molecular Gastroenterology and Hepatology|September 4, 2025
IL-4-mediated Pro-Regenerative Cellular Reprogramming in 3D Liver CultureDamra Camat, Diana Nakib, Sai W Chung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2025
The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 TrialAlison M Schram, Abdul Rafeh Naqash, Eric B Haura, et al.
NPJ Precision Oncology|February 14, 2024
Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapyCharlotte S Walmsley, Philip Jonsson, Michael L Cheng, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 28, 2023
Initial Chemotherapy for Locally Advanced and Metastatic NUT CarcinomaJia Luo, Michelle Sanchez, Elinton Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2022
Report of the First International Symposium on NUT CarcinomaChristopher A French, Michael L Cheng, Glenn J Hanna, et al.
The Oncologist|December 10, 2024
Associations of frailty with survival, hospitalization, functional decline, and toxicity among older adults with advanced non-small cell lung cancerHoward J Lee, John Boscardin, Louise C Walter, et al.
The New England Journal of Medicine|August 23, 2023
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a <i>KRAS</i> G12C MutationAdrian Sacher, Patricia LoRusso, Manish R Patel, et al.
Pageof 4